Calidi Biotherapeutics (CLDI) Cash from Financing Activities (2022 - 2025)

Calidi Biotherapeutics' Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $340000.0 for Q4 2025.

• In Q4 2025, Cash from Financing Activities fell 97.41% year-over-year to $340000.0; the TTM figure through Dec 2025 stood at $17.5 million (down 36.2% YoY), while the FY2025 annual figure was $17.5 million, down 36.2% from the prior year.
• Cash from Financing Activities for Q4 2025 stood at $340000.0, down from $9.5 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $21.6 million in Q3 2023, with the low at -$3.0 million in Q4 2023.
• The 4-year median for Cash from Financing Activities is $5.6 million (2024), against an average of $6.1 million.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities sank 168.49% in 2023, then soared 543.07% in 2024.
• Calidi Biotherapeutics' Cash from Financing Activities stood at $4.3 million in 2022, then slumped by 168.49% to -$3.0 million in 2023, then jumped by 543.07% to $13.1 million in 2024, then sank by 97.41% to $340000.0 in 2025.
• Business Quant data shows CLDI's Cash from Financing Activities at $340000.0 in Q4 2025, $9.5 million in Q3 2025, and -$469000.0 in Q2 2025.